The Federal Drug Administration Saturday night approved an Emergency Use Authorization for an antibody treatment President Donald Trump received shortly after being diagnosed with the Wuhan coronavirus. The manufacturer, Regeneron, received the green light for their cocktail of two antibodies – or casirivimab and imdevimab – that appear to be effective for those with mild to moderate coronavirus. The two antibodies, referred to as monoclonal antibodies, are created in a lab and mimic the human body's natural immune system. When administered the cocktail prevents the virus from attaching to human cells. In order to receive the treatment, a patient must...
